Corpus overview


Overview

MeSH Disease

Human Phenotype

Cough (2)

Diarrhea (2)

Fever (2)

Hypertension (2)


Transmission

Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    Analysis on Diagnosis of Family Clustering Infection of SARS-CoV-2

    Authors: Rong Qiu; Ming-wei Liu; Chuan Zhao; Wei-min Li

    doi:10.21203/rs.3.rs-21188/v1 Date: 2020-04-03 Source: ResearchSquare

    Background: Novel coronavirus (nCoV, SARS-CoV-2) infection MESHD has complicated and diversified symptoms, but no special treatment. In this study, diagnosis and treatment of family clustering nCoV infection MESHD were analyzed. Methods: The Sichuan Suining Central Hospital received 11 patients with confirmed nCoV virus infection MESHD from 4 families during January 23rd, 2020 to February 20th, 2020. Their clinical symptoms, treatment conditions and changes of disease state were reviewed in the present study. Results: In all 4 families, there were 1-2 members in each family TRANS who had contact with epidemic disease MESHD. Clinical manifestations were: 3 cases had debilitation only, 1 case had cough HP only, 1 case had diarrhea HP diarrhea MESHD, 5 cases had fever HP fever MESHD and cough HP cough MESHD, and 1 case had blood SERO-stained sputum. According to image changes, no image change was observed in 1 child TRANS patient. Multiple focal ground-glass opacities were detected from 2 patients and multiple patchy shadows were observed from 8 patients, especially in lung periphery. Complications: there were hypertension HP hypertension MESHD in 3 cases, diabetes MESHD in 2 cases, depression MESHD in 1 cases and hypertension HP hypertension MESHD and diabetes MESHD in 1 case. Moreover, there’s one patient who had rheumatic heart disease MESHD and received mitral and aortic valve replacement 2 years ago. All 11 cases divided into mild type (1 child TRANS patient), moderate type (8 patients), severe type (1 patient) and critical type (1 patient). Treatment: 11 patients were treated with intravenous drip of ribavirin injection ( adult TRANS 0.5g/time; child15mg/kg.time,twice per day) and lopinavir/ritonavior ( adult TRANS: 2 tablets/ time; child TRANS: 1/2 tablets/times, twice per day) for 6-12 days, accompanied with appropriate amount of intravenous drip of antibiotics. Discharge: After treatment, 11 patients met the discharge criteria and were allowed to discharge. Adverse reactions: 4 patients had loose stools and abdominal discomfort, and another 2 cases had diarrhea HP diarrhea MESHD. Conclusions: SARS-CoV-2 infection MESHD have complicated and diversified symptoms, which shall be identified according to epidemic history and novel coronavirus nucleic acid test. In particular, the whole family in which there’s a patient with confirmed SARS-CoV-2 shall be isolated for screening in addition to the patient. The lopinavir/ritonavior administration combined with ribavirin or recombinant Human Interferon (RHI) α2b is effective, accompanied with mild adverse reaction.

    Analysis on Diagnosis of Family Clustering Infection of SARS-CoV-2

    Authors: Rong Qiu; Ming-wei Liu; Chuan Zhao; Wei-min Li

    doi:10.21203/rs.3.rs-18076/v1 Date: 2020-03-18 Source: ResearchSquare

    Objective: Novel coronavirus (nCoV, SARS-CoV-2) infection MESHD becomes a world-wide epidemic which has complicated and diversified symptoms, but no special treatment. In this study, diagnosis and treatment of family clustering nCoV infection MESHD were analyzed.Methods: The Sichuan Suining Central Hospital received 11 patients with confirmed nCoV virus infection MESHD from 4 families during January 23rd, 2020 to February 20th, 2020. Their clinical symptoms, treatment conditions and changes of disease state were reviewed in the present study.Results: In all 4 families, there were 1-2 members in each family TRANS who had contact with epidemic disease MESHD. Clinical manifestations were: 3 cases had debilitation only, 1 case had cough HP only, 1 case had diarrhea HP diarrhea MESHD (a child TRANS patient of four years old), 5 cases had fever HP fever MESHD and cough HP cough MESHD, and 1 case had blood SERO-stained sputum. According to image changes, no image change was observed in 1 child TRANS patient. Multiple focal ground-glass opacities were detected from 2 patients and multiple patchy shadows were observed from 8 patients, especially in lung periphery. Complications with basic diseases: there were hypertension HP hypertension MESHD in 3 cases, diabetes MESHD in 2 cases, and hypertension HP hypertension MESHD and diabetes MESHD in 1 case. Moreover, there’s one patient who had rheumatic heart disease MESHD and received mitral and aortic valve replacement 2 years ago. There’s another one who had depression MESHD and suicidal tendency. All 11 cases divided into mild type (1 child TRANS patient), moderate type (8 patients), severe type (1 patient) and critical type (1 patient). Treatment: the mild child TRANS patient (4 years old) was administrated with 2.75ml lopinavir / ritonavir oral liquid (twice per day) and intravenous drip of 0.17g ribavirin injection (1ml: 0.1g*10pcs/box) every 12h for one week. Meanwhile, the child TRANS was asked to take azithromycin orally. 7 moderate patients were treated with intravenous drip of 0.5g ribavirin injection (1ml: 0.1g*10pcs/box) every 12h (twice per day) and two pieces of lopinavir/ritonavior (twice per day) for 7-10 days. In the same time, patients were given with reasonable amount of antibiotics by oral or intravenous drip. 1 severe patient and 1 critical patent were treated with 5,000,000 U recombinant human interferon α2b injection (3,000,000 U/pc) and aerosol inhalation of 2ml sterile water for injection (5ml*50 pcs/ box), twice per day. Besides, they took 2 pieces of lopinavir/ritonavior, twice per day. The whole treatment program lasted for 6-12 days, accompanied with appropriate amount of intravenous drip of antibiotics. The critical patient was also provided with mechanical ventilation. During the treatment, severe and critical patients were treated by resochin for 4-5 days for evident respiratory symptoms. One moderate patient was treated with 2 pieces of lopinavir/ritonavior, twice per day. In the same time, it was administrated by intravenous drip of antibiotics. However, resochin treatment was applied for positive novel coronavirus nucleic acid of respiratory sputum specimen after 11 days of treatment. Discharge: After treatment, patients with body temperatures of all patients recovered to normal level, and respiratory symptoms and digestive tract symptoms relieved significantly, significant coefficient of exudative lesion at lung according to chest CT and negative novel coronavirus nucleic acid of continuous two respiratory sputum specimens (sampling interval was at least 1 day) were allowed to be discharged. Adverse reactions: 4 patients had loose stools and abdominal discomfort, and another 2 cases had diarrhea HP diarrhea MESHD.Conclusions: SARS-CoV-2 infection MESHD have complicated and diversified symptoms, which shall be identified according to epidemic history and novel coronavirus nucleic acid test. In particular, the whole family in which there’s a patient with confirmed SARS-CoV-2 shall be isolated for screening in addition to the patient. The lopinavir/ritonavior administration combined with ribavirin or recombinant Human Interferon (RHI) α2b is effective, accompanied with mild adverse reaction. If lopinavir/ritonavior administration and / or combined with ribavirin and RHI α2b is invalid, adding resochin might be effective.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.